secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104104
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts
--------------------------------------------------------------------------------

- Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.
- Cash and equivalents $59.1M as of Dec 31, 2025.
- PIKture-01 trial (OKI-219) data expected March 2026 across mono, combo, and triplet arms.
- Next-gen PI3Kα pan-mutant inhibitor candidate for HR+ breast cancer to be announced March 2026.
- R&D expenses $10.7M vs $14.4M YoY; G&A $3.4M vs $4.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312526104104/0001193125-26-104104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312526104104/okur-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer